Bucci Tommaso, Menichelli Danilo, Palumbo Ilaria Maria, Pastori Daniele, Ames Paul R J, Lip Gregory Y H, Pignatelli Pasquale
Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool and Heart and Chest Hospital, Liverpool, L7 8TX, UK.
Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
Cells. 2025 Feb 28;14(5):353. doi: 10.3390/cells14050353.
The thrombotic physiopathology of antiphospholipid syndrome (APS) is complex, heterogeneous, and dynamic. While venous thromboembolism (VTE) is the most common initial presentation, arterial thrombotic events (ATE) become more frequent in advanced stages and are associated with high morbidity and mortality. Despite the use of oral anticoagulants (OACs), thrombotic APS remains associated with a high risk of recurrent thrombosis. Given their potential antithrombotic effects capable of reducing the risk of both VTE and ATE, statins have been proposed as an adjunctive therapy to OACs for patients with APS and recurrent thrombosis. However, this recommendation is primarily based on studies not specifically conducted in APS populations, with only preclinical data or evidence from retrospective observational studies available from APS patients cohorts. For these reasons, this narrative review aims to synthesise the studies evaluating the potential antithrombotic effects of statins in patients with APS, highlighting the progress made and identifying areas for future research.
抗磷脂综合征（APS）的血栓形成病理生理学复杂、异质性强且具有动态变化。静脉血栓栓塞（VTE）是最常见的初始表现，而动脉血栓事件（ATE）在疾病晚期更为频繁，且与高发病率和死亡率相关。尽管使用了口服抗凝剂（OAC），血栓形成性APS仍与复发性血栓形成的高风险相关。鉴于他汀类药物具有潜在的抗血栓作用，能够降低VTE和ATE的风险，因此已有人提出将他汀类药物作为OAC的辅助治疗药物，用于患有APS和复发性血栓形成的患者。然而，这一建议主要基于并非专门针对APS人群开展的研究，仅有来自APS患者队列的临床前数据或回顾性观察性研究的证据。基于这些原因，本叙述性综述旨在综合评估他汀类药物对APS患者潜在抗血栓作用的研究，突出已取得的进展，并确定未来的研究方向。
